ZURA nears pivotal-trial readouts for IL-17/BAFF bispecific in autoimmunity
ZURA says upcoming pivotal-trial data in hidradenitis suppurativa and systemic sclerosis will test a bispecific antibody targeting IL-17 and BAFF, aiming to address efficacy ceilings in autoimmune diseases.
Upcoming data from pivotal trials in hidradenitis suppurativa and systemic sclerosis will test a bispecific antibody targeting IL-17 and BAFF, with the program aimed at addressing efficacy ceilings in autoimmune diseases. The pipeline also includes additional assets with recent external validation, and further updates are expected.